Does Weight Impact Anidulafungin Pharmacokinetics?

Vincent J. Lempers, Anne van Rongen, Eric P. van Dongen, Bert van Ramshorst, David M. Burger, Rob E. Aarnoutse, Catherijne A. Knibbe, Roger J. Brüggemann

Research output: Contribution to journalArticlepeer-review

20 Citations (Scopus)

Abstract

Bodyweight has been shown to influence anidulafungin exposure, but data from obese patients are lacking. We determined anidulafungin pharmacokinetics (100-mg single dose) in eight morbidly obese subjects (body mass index >40 kg/m2). Anidulafungin exposure was on average 32.5 % lower compared with the general patient population, suggesting dose increases may be required in this population.

Original languageEnglish
Pages (from-to)1289-1294
Number of pages6
JournalClinical Pharmacokinetics
Volume55
Issue number10
DOIs
Publication statusPublished - 1 Oct 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Does Weight Impact Anidulafungin Pharmacokinetics?'. Together they form a unique fingerprint.

Cite this